PublizoomAward notice Supplies
Médicaments antinéoplasiques (ATC L01) et autres immunosuppresseurs (ATC L04AX)
Notice published in French. The AI analysis summarises it for you in your language.
- Public buyer
- Healthcare Public Procurement (HeCaPP)
Saint-Gilles\Sint-Gillis - Place of performance
- 1020 Bruxelles\Brussel, Brussels-Capital
- Amount awarded
- €661,259 excl. VAT
- Planned end of contract
- 5 August 2029
likely re-tender around February 2029 - Bids received
- 3
- Procedure
- Open procedure
Any company may submit a bid. - Publication
- 8 August 2025
- Notice language
- French
AI analysis: go for it or not?
Summary in English, criteria, documents to provide and a GO / NO GO verdict in one minute.
Unlimited analyses during the 14-day Pro trial, no card needed.
Description
Médicaments antinéoplasiques (ATC L01) et autres immunosuppresseurs (ATC L04AX)
Awarded to
8 lots
- Méthotrexate 50mg/mL (injectable)
- Azacitidine 25mg/mL (injectable)
- Capecitabine (voie orale)
- Cisplatine 1mg/ mL (injectable)
- Irinotecan 20 mg / mL (injectable)
- Etoposide 20mg/mL(injectable)
- Sorafénib 200mg (voie orale)
- Doxorubicine liposomale 2mg/mL (injectable)
CPV codes
European codes that classify what the contract is about. They are how we find the tenders for your trade.
33600000
Winning prices for comparable contracts
- A quarter below
- €269,390
- Median
- €449,863
- A quarter above
- €962,736
Amounts awarded (excl. VAT) over the last 3 years for 58 contracts in the same CPV group (3360…), excluding framework agreements. Half of the contracts fall between the two quartiles. TED source: mostly contracts above the EU thresholds, so amounts tend to be high.
Similar contracts already awarded
Source : TED – Office des publications de l'Union européenne © Union européenne, données retraitées. Reference 520995-2025.